Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AntiPCO: Cyproterone-Spironolactone vs Metformin vs Pioglitazone in PCOS
NCT02689843Phase 1Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cyproterone, ethinyl estradiol, spironolactone, liquid metformin (Aspargo Labs) and pioglitazone in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Serum C3 at 3 months, Serum C4 at 3 months and 1 more. Started Feb 2018; status: completed.
02
Drugs
cyproteroneethinyl estradiolspironolactoneliquid metformin (Aspargo Labs)pioglitazone
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT02689843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689843.